Expert US stock capital allocation track record and investment grade assessment for management quality evaluation. We evaluate how well management has historically deployed capital to create shareholder value.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Most Discussed Stocks
REGN - Stock Analysis
3652 Comments
991 Likes
1
Kreena
Engaged Reader
2 hours ago
This feels like something I shouldn’t know.
👍 290
Reply
2
Nahshon
Loyal User
5 hours ago
Really missed out… oof. 😅
👍 95
Reply
3
Katalyna
Returning User
1 day ago
Really wish I had known before.
👍 202
Reply
4
Darivs
Experienced Member
1 day ago
Trading activity suggests measured optimism among investors.
👍 182
Reply
5
Andreu
Insight Reader
2 days ago
Really wish I had read this earlier.
👍 269
Reply
© 2026 Market Analysis. All data is for informational purposes only.